By Gabriel Paijo 
A landmark clinical trial conducted by researchers at Intermountain Health in Salt Lake City has revealed that a precision-based approach to vitamin D3 supplementation can significantly alter the recovery trajectory for heart attack survivors. The study, known as the TARGET-D trial, demonstrates that tailoring vitamin D3 dosages to reach specific blood level targets—rather than administering a standard, one-size-fits-all supplement—can reduce the risk of a secondary heart attack by 50%. These findings, presented on November 9 at the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, represent a potential paradigm shift in post-myocardial infarction care and emphasize the growing importance of precision medicine in cardiovascular health.
The core of the study’s success lies in its "target-to-treat" methodology. Unlike previous clinical investigations that provided uniform doses of vitamin D to all participants, the Intermountain team actively monitored patients’ blood levels and adjusted their intake of vitamin D3 until they reached an optimal physiological range. This proactive management addressed a long-standing gap in nutritional science: the high variability in how individual bodies metabolize and respond to supplements. By ensuring that every patient in the treatment group achieved a blood concentration of at least 40 nanograms per milliliter (ng/mL), the researchers were able to unlock the protective cardiovascular benefits that had remained elusive in prior large-scale trials.
The Biological Context of Vitamin D and Heart Health
For decades, observational studies have consistently shown a correlation between low vitamin D levels and an increased risk of heart disease, stroke, and hypertension. Vitamin D is not merely a nutrient but a pro-hormone that interacts with receptors located throughout the cardiovascular system, including the heart muscle (myocardium) and the lining of the blood vessels (endothelium). It is believed to play a critical role in regulating inflammation, managing blood pressure through the renin-angiotensin system, and preventing the calcification of arteries.
Despite these observational links, the medical community has remained skeptical because early randomized controlled trials (RCTs) often failed to show that supplementation actually prevented heart attacks. Experts now believe those earlier failures were likely due to insufficient dosing and a lack of follow-up testing. The TARGET-D trial addresses these shortcomings by treating vitamin D more like a prescription medication—with titration and regular monitoring—rather than a passive dietary addition.
The global implications of these findings are substantial. Current estimates suggest that between 50% and 66% of the world’s population suffers from some degree of vitamin D deficiency. Historically, humans synthesized the majority of their vitamin D through skin exposure to ultraviolet B (UVB) radiation from sunlight. However, modern lifestyle shifts—including more time spent indoors and the necessary use of sunscreen to prevent skin cancer—have led to a widespread decline in natural vitamin D production. For many, diet alone is insufficient to compensate for this deficit, making supplementation a vital, yet often misunderstood, tool in preventative medicine.
Chronology and Design of the TARGET-D Trial
The TARGET-D trial was a multi-year undertaking that began in April 2017. Researchers at Intermountain Health enrolled 630 patients who had recently experienced a heart attack, specifically within 30 days of their enrollment. The timing was intentional, as the period immediately following a major cardiac event is when a patient is at the highest risk for a secondary, often more fatal, event.
Upon enrollment, the participants were randomly divided into two distinct cohorts. The control group received standard post-heart attack care, which did not include formal vitamin D management. The intervention group, however, was placed on the "target-to-treat" protocol. At the start of the study, a staggering 85% of the participants were found to have vitamin D levels below the 40 ng/mL threshold, confirming the prevalence of deficiency among cardiac patients.
The dosing regimen for the intervention group was aggressive compared to standard guidelines. While the typical recommended dietary allowance (RDA) for vitamin D ranges from 600 to 800 international units (IU) per day, more than half of the patients in the TARGET-D trial required an initial daily dose of 5,000 IU to begin moving toward the target.
The trial’s timeline extended through May 2023, with a follow-up period lasting until March 2025 to capture long-term cardiovascular outcomes. During this window, patients in the treatment group underwent blood tests every three months if their levels were low. Once they hit the 40 ng/mL target, they transitioned to annual testing to ensure they remained within the therapeutic range. This rigorous monitoring allowed the research team to gather precise data on the relationship between sustained vitamin D levels and cardiac health.
Analyzing the Data: MACE and Recurrent Myocardial Infarction
The primary objective of the study was to track Major Adverse Cardiovascular Events (MACE), a composite metric that includes heart attacks, strokes, hospitalizations for heart failure, and cardiovascular-related deaths. Throughout the study, 107 of the 630 participants experienced at least one event categorized as MACE.
When analyzing the broad MACE composite, the researchers found that while there was a trend toward better outcomes in the vitamin D group, the difference was not statistically significant across all categories combined. However, when the data was disaggregated to look specifically at recurrent heart attacks, the results were striking. The group receiving targeted vitamin D3 treatment saw a 50% reduction in the incidence of a second heart attack compared to the control group.
Dr. Heidi May, PhD, a cardiovascular epidemiologist at Intermountain Health and the study’s principal investigator, highlighted the significance of these findings. "We observed no adverse outcomes when giving patients higher doses of vitamin D3 supplementation," Dr. May stated. "To significantly reduce the risk of another heart attack is an exciting result. We have seen in the past that standard doses didn’t do much, but when we checked exactly how supplementation was working and made adjustments, we found that patients had their risk cut in half."
Expert Reactions and Clinical Implications
The presentation of the TARGET-D results at the American Heart Association Scientific Sessions has sparked significant discussion among cardiologists and nutritional scientists. For years, the "Vitamin D Paradox"—the gap between observational benefits and clinical trial failures—has frustrated clinicians. This study provides a potential roadmap for resolving that paradox through personalized dosing.
Medical professionals not involved in the study have noted that the 40 ng/mL target is notably higher than the 20-30 ng/mL range often considered "sufficient" by many labs. This suggests that the threshold for cardiovascular protection may be higher than the threshold for bone health, which has historically dictated vitamin D guidelines.
"The findings from the TARGET-D trial underscore the necessity of moving away from ‘one-size-fits-all’ nutrition in clinical settings," said one independent commentator at the AHA sessions. "If these results are validated in larger cohorts, checking vitamin D levels could become as routine as checking LDL cholesterol or blood pressure following a heart attack."
The study also reinforces the safety profile of higher-dose vitamin D3. There have long been concerns about vitamin D toxicity, which can lead to hypercalcemia (excess calcium in the blood). However, the Intermountain researchers reported no such adverse effects even with doses as high as 5,000 IU and blood levels exceeding 40 ng/mL, suggesting that with proper medical supervision, higher doses are both safe and effective.
Future Directions and the Path to New Guidelines
While the 50% reduction in recurrent heart attacks is a major breakthrough, the researchers at Intermountain Health are quick to note that this is a starting point rather than a final conclusion. The TARGET-D trial, while robust, consisted of 630 patients. To change international clinical guidelines, larger, multi-center trials will be required to confirm the findings across more diverse populations.
Dr. May and her team are already planning an expanded study. "A larger study group will allow us to more fully evaluate whether targeted vitamin D management can reduce not only repeat heart attacks but also other forms of cardiovascular disease, such as heart failure and stroke," she explained.
The broader impact of this research could extend to how health systems approach preventative care. If a relatively inexpensive supplement like vitamin D3, when managed correctly, can halve the rate of recurrent heart attacks, the cost-to-benefit ratio for healthcare providers would be extraordinary. Recurrent heart attacks are not only devastating for patients but are also a massive financial burden on healthcare systems due to emergency interventions, prolonged hospitalizations, and long-term disability.
As the medical community digests the results of the TARGET-D trial, the focus remains on the power of precision. The study serves as a reminder that in the era of modern medicine, the most effective treatments are often those that are tailored to the unique biological needs of the individual. For heart attack survivors, the message from Salt Lake City is clear: checking your vitamin D levels might be just as important as taking your beta-blockers or statins. The journey from a standard supplement to a targeted therapy may very well be the key to a longer, healthier life after a cardiac event.
